Press Release: VOI : Analysis Shows Amgen's Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag

In an environment where orphan drugs with price tags easily exceeding $100,000 per patient are receiving considerable attention, it may come as a surprise to find that published prices and actual cost-of-therapy can be two very different things. As demonstrated in a new analysis from life-sciences advisory firm, VOI Consulting, this is the case for at least one notable entrant in the ultra-high cost category.(PRWeb September 02, 2015)Read the full story at http://www.prweb.com/releases/amgens-blincyto-ultra-exp/09/prweb12938343.htm